Pharmaceutical company Dr Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) stated on Friday that it has launched the US Food and Drug Administration (USFDA) approved Deferasirox Tablets for oral suspension in the US market.
According to the company, Deferasirox Tablets for oral suspension are available in 125 mg, 250 mg and 500 mg dosage strengths in bottle count sizes of 30.
Dr Reddy's Deferasirox Tablets for oral suspension are a therapeutically equivalent generic version of Exjade (deferasirox) tablets for oral suspension.
For the most recent 12 months ending in September 2019, the Exjade brand had US sales of about USD113m MAT, according to IQVIA Health. Exjade (deferasirox) tablets for oral suspension are indicated for the treatment of chronically elevated levels of iron in the blood caused by repeated blood transfusions (transfusional hemosiderosis) in patients two years of age and older.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling